Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Public offering nets $189mm for Endocyte

Executive Summary

Endocyte Inc. (targeted cancer therapies and companion imaging agents) netted $189mm through the public sale of 10.9mm common shares (including the overallotment) at $18.50. Proceeds will support continued pipeline development and commercial launch preparation for 177Lu-PSMA617, a radioligand therapeutic currently in a Phase III trial for progressive PSMA-positive metastatic castration-resistant prostate cancer.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
  • Pharmaceuticals
    • Drug Delivery
    • Radiopharmaceuticals, Contrast Agents
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies